We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Aurora Diagnostics Cancels Plans for an IPO

By LabMedica International staff writers
Posted on 20 Jun 2012
Aurora Diagnostics (Palm Beach Gardens, FL, USA), a specialized diagnostics company focusing on the anatomic pathology market, canceled its long-delayed plans for an initial public offering (IPO) on June 6, 2012. The company asked the US Securities and Exchange Commission (SEC) to withdraw its registration statement because it had decided not to pursue an initial public offering (IPO) or stock market launch.

In April 2010, Aurora Diagnostics was seeking to raise up to USD 150 million. Although it never set a date or price for that offering, the company updated its financial results every quarter to keep its eligibility for the offering current. It even held several conference calls for prospective investors. Aurora Diagnostics raised USD 200 million in December 2010 through a private bond placement.

Aurora Diagnostics lost USD 32.9 million in 2011 on revenue of USD 277.5 million, compared with a USD 3.7 million loss on revenue of USD 212.8 million the year before. It followed that up in the first quarter with a USD 2.1 million loss on revenue of USD 72.1 million, compared with a USD 2 million loss on revenue of USD 62.6 million in the same period a year ago.

Related Links:

Aurora Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Urine Analyzer
respons® UDS100
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
20 Jun 2012  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
20 Jun 2012  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
20 Jun 2012  |   Industry